Much of our in house research is directed towards development of new treatments whether they be pharmacological, gene-based or cell based. Our portfolio of activities includes anti-scarring treatment for glaucoma, gene therapy for a wide range of ocular conditions, cell transplantation including stem cell developments and preventive treatments for AMD. We have a strong track record in the development of new imaging technologies including fundus autofluorescence. Particularly exciting is the recent development of tools to visualise retinal cells dying by apoptosis in the living eye. We are currently working to establish reliable assessment of disease progression in glaucoma.
You need to upgrade your Flash Player